Search Results

You are looking at 141 - 150 of 431 items for :

  • "Adjuvant therapy" x
  • All content x
Clear All
Full access

.” Approximately half of patients with metastatic melanoma harbor an activating mutation of BRAF, a signaling kinase. These patients tend to show dramatic responses to vemurafenib. Other updates include expanded recommendations on adjuvant therapy and radiation

Full access

imaging specialists, and pulmonologists. “Radiation is recommended as an adjuvant therapy to improve local control after surgery, and it is also an effective palliative treatment for relief of chest pain that is often associated with mesothelioma,” said

Full access

Marsha Reyngold, Joyce Niland, Anna ter Veer, Dana Milne, Tanios Bekaii-Saab, Steven J. Cohen, Lily Lai, Deborah Schrag, John M. Skibber, William Small Jr, Martin Weiser, Neal Wilkinson, and Karyn A. Goodman

adjuvant therapy data (n=3). A total of 29 patients received postoperative RT and were excluded from the analysis of factors associated with omission of preoperative RT. The minimum follow-up time was 120 days for all patients. Variables Analyzed

Full access

Ariel Polish and Mary F. Mulcahy

neoadjuvant or adjuvant therapy. One retrospective study focused on 49 patients with adenocarcinoma (90%) or squamous (10%) cancer of the esophagus who were staged as T2,N0,M0 and received neoadjuvant chemoradiation. 14 The study found that the 5-year rates

Full access

Janice S. Kwon, Gary Pansegrau, Melica Nourmoussavi, Geoffrey L. Hammond, and Mark S. Carey

. Goss PE Ingle JN Pritchard KI . Extending aromatase-inhibitor adjuvant therapy to 10 years . N Engl J Med 2016 ; 375 : 209 – 219 . 4. Goss PE Ingle JN Martino S . Impact of premenopausal status at breast cancer diagnosis in women entered

Full access

Daniel G. Coit and Anthony J. Olszanski

considered at high risk for recurrence after adjuvant therapy, interferon-alfa appears to confer a small benefit. The value of high-dose interferon was first established in 1996 by Kirkwood et al. 5 for patients with T4 lesions or evidence of regional

Full access

Melinda L. Telli, William J. Gradishar, and John H. Ward

personalize systemic adjuvant therapy choices,” Dr. Ward said. “The available assays have strong prognostic capability, and more data on this are coming.” Among the available assays are the 21-gene panel (Oncotype Dx), the 70-gene panel (MammaPrint), the 50

Full access

Sara H. Javid, L. Christine Fang, Larissa Korde, and Benjamin O. Anderson

34%, 1 , 3 a favorable outcome that has been attributed to the combination of increased screening mammography and improved adjuvant therapy. 4 However, despite the steady increase in DCIS detection and treatment in the 1990s, the subsequent

Full access

Jordan M. Cloyd, Chengli Shen, Heena Santry, John Bridges, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik, and Allan Tsung

greater number of patients will be unable to complete the intended course of adjuvant therapy for similar reasons. 7 , 8 The administration of chemotherapy with or without radiation therapy (RT) before surgical resection is an alternative strategy that

Full access

Sharon H. Giordano, Anthony D. Elias, and William J. Gradishar

for advanced hormone-sensitive breast cancer at the NCCN 23rd Annual Conference. New Adjuvant Therapy Options for Patients With HER2-Positive Cancer Two new adjuvant treatment options for patients with HER2-positive disease are in the 2018 NCCN